SESSIONSFORUMS AND WORKSHOPS (OCTOBER 8)

Connecting Nordic & Baltic Innovators With Capital 8th-9th October 2024 Bella Center, Copenhagen, Denmark

Biotech Growth CEO Forum

11:00 - 12:45 CEO Forums & Workshops

The Biotech Growth CEO Forum provides a unique, powerful and valuable space for the candid sharing of ideas and experience between 15-25 c-suite executives from privately-held life science companies from the Nordic region.

The forum is designed to generate new ideas to take back to the office and new relationships between peers.

The forum features presentations or specific case studies from CEOs and partners focused on either success stories or current challenges.

Through group discussion you'll be able to:

- · Benchmark yourself against your peers
- Uncover key factors of success
- Share war stories and common challenges
- · Engage in peer-to-peer discussion
- Make meaningful connections
- · Find new ways to help your business thrive

It follows a <u>Chatham House Rule</u> policy where all participants are active discussants.

Lunch Break

12:45 - 13:45 Break

Healthtech CEO Forum

13:45 - 14:45 CEO Forums & Workshops

The Healthtech CEO Forum provides a unique, powerful and valuable space for the candid sharing of ideas and experience between 15-25 c-suite executives from health technology and digital health companies.

The forum is designed to generate new ideas to take back to the office and new relationships between peers.

The forum features presentations or specific case studies from CEOs and partners focused on either success stories or current challenges.

Through group discussion you'll be able to:

- · Benchmark yourself against your peers
- Uncover key factors of success
- · Share war stories and common challenges
- · Engage in peer-to-peer discussion
- · Make meaningful connections
- · Find new ways to help your business thrive

It follows a <u>Chatham House Rule</u> policy where all participants are active discussants.

IPO Workshop: Approaches to Going Public in the Nordics

14:45 - 16:30 CEO Forums & Workshops

Nordic companies considering going public in the region are once again in the limelight. There are pros, cons, challenges and efficiencies to various approaches, which will be the focus of this workshop.

- Overview of Nordic IPO market trends and options for going public
- 2. Approaches to listing in the Nordics
 - 1. SPACs
 - 2. Traditional IPOs
 - 3. Direct Listings
 - 4. Key considerations, benefits and challenges
- 3. Specific considerations for dual-listed companies
- Case studies successful company case study on going public in the Nordics
- Discussion and attendee Q&A

Networking Drinks

16:30 - 17:30 Break



TIME	CEO FORUMS & WORKSHOPS	BREAK
11:00	11:00 - Biotech Growth CEO Forum	
12:00		12:45 - Lunch Break
13:00	13:45 - Healthtech CEO Forum	
14:00	14:45 - IPO Workshop: Approaches to Going Public in the Nordics	
16:00		16:30 - Networking Drinks

SESSIONSFORUMS AND WORKSHOPS (OCTOBER 9)

LSX Nordic Congress

Connecting Nordic & Baltic Innovators With Capital 8th-9th October 2024 Bella Center, Copenhagen, Denmark

Medtech CEO Forum

11:00 - 12:00 Workshop

The Medtech CEO Forum provides a unique, powerful and valuable space for the candid sharing of ideas and experience between 15-25 c-suite executives from medical technology companies.

The forum is designed to generate new ideas to take back to the office and new relationships between peers.

The forum features presentations or specific case studies from CEOs and partners focused on either success stories or current challenges.

Through group discussion you'll be able to:

- · Benchmark yourself against your peers
- · Uncover key factors of success
- · Share war stories and common challenges
- · Engage in peer-to-peer discussion
- · Make meaningful connections
- · Find new ways to help your business thrive

It follows a <u>Chatham House Rule</u> policy where all participants are active discussants.





TIME	WORKSHOP
11:00	11:00 - Medtech CEO Forum

SESSIONS

DAY 1 - TUESDAY 8TH OCTOBER - 08/10/2024

Connecting Nordic & Baltic Innovators With Capital 8th-9th October 2024 Bella Center, Copenhagen, Denmark

LSX Opening Address

08:50 - 08:55 Keynote Plenary

Participants

Josh Dance - Managing Director, LSX

Live Opening of The Nasdaq Nordic Markets & Nasdaq Welcome

08:55 - 09:10 Keynote Plenary

Participants

Adam Kostyál - President, Nasdaq

Carsten Borring - Head of Listings & Capital Markets, NASDAQ

The Thriving Life Science Ecosystem in the Nordic Region: Evolution, Current Landscape, and Future Outlook

09:10 - 09:50 Keynote Plenary

The Nordic region's life science ecosystem has evolved from its academic roots into a thriving hub of innovation, investment, and collaboration. With a strong foundation in research excellence, a supportive regulatory environment, and a focus on advanced, therapies, the Nordics are poised to maintain their position as a global leader in the life sciences. As the sector continues to evolve, international partnerships, digital integration, and sustainability will shape its trajectory, ensuring a bright future for the Nordic life science.

- The rise of the Nordic life science region as a global hub of innovation: Evolution and current landscape in 2024 and beyond
- Unique strengths and qualities of Nordic Life Science startups which allow for successful international growth
- With fundraising opportunities once again increasing, how can biotechs, medtechs, and healthtechs navigate the current markets to ensure future success and stability?

Participants

Adam Kostyál - President, Nasdaq

Christof Bischoff - Country Director, Denmark, AstraZeneca

Stephan Christgau - Founding Partner, Eir Ventures **Henrijette Richter** - Partner , Sofinnova Partners

The 2030 Vision: The Economic Potential and Future of Nordic Healthcare

09:50 - 10:30 Keynote Plenary

Worldwide, the Nordic Region is the 10th largest economy by GDP. Continuously ranked high on digitalization and productivity, the Nordic region faces an incoming challenge of a radical demography shift, whereby the ratio of elderly to young is set to increase drastically by 2024. An increase in healthcare expenditure with an ageing population runs the risk of increase in chronic illness and mental health issues. Thus a new, integrated and sustainable healthcare system could transform the Nordic region to provide the best possible personalized health care for its entire population by 2030. To be successful in an integrated, cross-border sharing of Nordic health data will require disruptive thinking and increased collaboration, and likely to result in a significant positive economic impact.

- · How exactly can health data be leveraged to make the Nordic vision a reality?
- · Key challenges and opportunities of making real a new integrated and sustainable healthcare system
- · Potential economic effects on the Nordic region

Participants

Bogi Eliasen - Director of Health, Copenhagen Institute for Future Studies

Troels Bierman Mortensen - CEO, DataFair

Frederik Knud Nielsen - Healthcare Partnerships Director, Novartis Denmark

Kenneth Forsstrøm Jensen - Health Data Lead, Roche

Morning Break

10:30 - 11:00 Break

Nordic Biotechs Beyond Borders: Public-Stage Nordic Biotech's in Today's Markets

11:00 - 11:50 BIOTECH LEADERS

In the dynamic arena of public markets, Nordic biotech companies are stepping onto the global stage, presenting both unprecedented opportunities and challenges. This panel delves into the strategies, experiences, and trends that define the journey of public stage Nordic biotechs in the current market landscape. From initial public offerings to sustaining momentum post-listing, our expert panellists will share insights, lessons learned, and visionary perspectives on how these companies can thrive under the scrutiny of public investors while contributing to the burgeoning innovation ecosystem in the Nordic region.

- · Assessing the current state of the public markets
- Delving into effective strategies for Nordic biotechs to enter and establish a foothold in new international markets, including considerations for regulatory compliance and cultural nuances
- The importance of building robust global networks and partnerships, exploring how collaborations with international stakeholders contribute to market access, distribution, and product adoption.
- Exploring how public stage Nordic biotechs can navigate the complexities of sustaining growth, maintaining innovation momentum, and meeting the expectations of shareholders and the broader market post-IPO
- How strategic partnerships and collaborations contribute to market presence, product development, and overall competitiveness

Participants

Renee Aguiar-Lucander - CEO, Calliditas Therapeutics

Jens Lindberg - CEO, Medivir

Per Andersson - CEO, Xspray pharma

Søren Bregenholt - CEO, Alligator Biosciences

SESSIONS

DAY 1 - TUESDAY 8TH OCTOBER - 08/10/2024

Connecting Nordic & Baltic Innovators With Capital 8th-9th October 2024 Bella Center, Copenhagen, Denmark

Our AI Future is Now - Utilising Gen AI & LLMs to Solve Healthcare Challenges

11:00 - 11:40 MEDTECH & HEALTHTECH LEADERS

The anticipation and excitement around AI is huge, how are these novel technologies shaping the industry? How can we apply these new technologies into healthcare, and overcome social, ethics & regulatory barriers to implementation?

- Leveraging generative AI tools & large language models to solve unmet medical needs and optimise care delivery
- EU AI Act How will this legislation affect digital health and medtech companies? • AI use to improve the patient and consumer experience – what about less obvious use cases for AI?
- Managing consumer and patient expectations in the age of AI
- Effective safeguards for responsible Al use (ethical frameworks, diversity & inclusion in Al development etc.)

Participants

Farzaneh Etminani - Al Strategist, Region Halland

Lauri Sippola - Co-founder & CEO, Gosta Labs

Jussi Leinonen - Strategic Project Lead, Bayer

Henriikka Halinen - Business Leader, Emergency Care, Western Europe, Philips

Digital Health Reimbursement & Adoption Across Europe - Strategies for Overcoming Fragmented Digital Markets

11:40 - 12:25 MEDTECH & HEALTHTECH LEADERS

- Evaluating the reimbursement pathways and frameworks across Europe
- Where are we at? Which countries pathways/ frameworks are working best
- Overcoming barriers of adoption
- Strategies for thriving in Europe's fragmented digital health markets
- Expanding and scaling into a new market success stories

Participants

Andreas Dam - Founder & CEO, HealthBuddy

Troels Bierman Mortensen - CEO, DataFair

Merilin Varsamaa - Head of Health Technology, Technopol

Northern Horizons: Navigating the Nordic Biotech Investment Frontier in 2024 and Beyond

11:50 - 12:40 BIOTECH LEADERS

As the biotech landscape continues its rapid evolution, the Nordic region endures as a focal point of innovation and investment opportunities. This panel discussion dives into the intricacies of the Nordic biotech investment landscape in 2024 and beyond. Our esteemed panellists will dissect current trends, examine the unique challenges and opportunities within the Nordic ecosystem, and forecast the potential trajectories that investors, startups, and industry stakeholders can anticipate.

- Highlighting how the Nordic biotech ecosystem has demonstrated success in the face of global challenges
- · Exploring factors contributing to stability
- Unveiling the latest trends and cutting-edge technologies driving biotech advancements in the Nordic region, and discussing their implications for investors and startups
- Shifting investment strategies in an evolving regulatory environment, and attracting and retaining investment in Nordic biotech

Participants

Giovanni Rizzo - Partner Biotech Fund, Indaco Venture Partners

Jeroen Bakker - Partner, Novo Holdings

Ingrid Teigland Akay - Managing Partner, Hadean Ventures

Ward Capoen - Partner, V-Bio Ventures

Lunch Break

12:40 - 13:50 Break

AI – A Game Changer for the Future of Nordic Life Sciences

13:50 - 14:40 BIOTECH LEADERS

As the convergence between artificial intelligence (AI) and life sciences in the Nordic region continues to advance, this panel discussion aims to bring together visionaries, researchers, and industry leaders to illuminate the groundbreaking advancements, challenges, and future trajectories of AI within the dynamic landscape of the nordics. From drug discovery to personalized medicine, the Nordic countries are at the forefront of integrating AI technologies, shaping the future of healthcare and scientific innovation. Join us for a captivating conversation as we unravel the intricate tapestry of AI's impact on life sciences in the Nordics.

- Delving into how AI is revolutionizing the drug discovery process in the Nordic life sciences sector.
- Exploring the role of AI in advancing precision medicine and personalized healthcare initiatives across the Nordic region - how are AI algorithms enhancing patient outcomes, while ensuring a tailored approach to individual health needs?
- 3. Discussing the ethical considerations surrounding the use of AI in life science. How are Nordic countries addressing concerns related to data privacy, security, and the responsible deployment of AI technologies?
- 4. Highlighting collaborative efforts and knowledge exchange platforms that facilitate the integration of AI in Nordic life sciences. How can we harness the full potential of AI, and what lessons can be shared with the global scientific community?

Participants

Magnus Nyden - Head of Innovation, AstraZeneca

Beth Wolff - Director Digital Health Solutions, Global Corporate Strategy & BD, Lundbeck

Hisham Hamadeh - SVP, Global Head of Data Science & AI, Genmab

SESSIONS

DAY 1 - TUESDAY 8TH OCTOBER - 08/10/2024

Connecting Nordic & Baltic Innovators With Capital 8th-9th October 2024 Bella Center, Copenhagen, Denmark

Sourcing Innovation – Deal Activity & Partnerships With Big Strategics

13:50 - 14:40 MEDTECH & HEALTHTECH LEADERS

With the appetite for in-house R&D increasingly reducing for big Medtech and Pharma, the opportunity is ripe for medtech and healthtech companies to position themselves as the next 'must-have' partner. This panel takes a look at the current deal-making market, and how big strategics are playing their cards.

- How has the sector recovered and processed the deal overhang in 2024?
- Making your company 'acquisition & partnership' ready
- What happens 'behind the scenes' as a deal is negotiated?
- Large medtech and pharma and private equity deal appetite for 2025

Participants

Malin Johannson - VP, Digital Health Partnerships & Commercialisation, Novo Nordisk

Roger Gunnarsson - Senior Advisor, Segulah Medical Accelaration

Mauricio Benavente - Senior Director Business Development & Licensing (M&A), Baxter

Baltoscandia: The Baltic Investors' Perspective on the Nordic Markets

14:40 - 15:30 BIOTECH LEADERS

In recent years, the economic landscape of the Baltic Sea region, 'Baltoscandia', has witnessed significant transformation. This area has emerged as a hotspot for investors eyeing the Nordic markets. With its strategic location, skilled workforce, and growing tech scene, Baltoscandia presents a unique opportunity for investors seeking to tap into the dynamic Nordic economy. This panel discussion aims to explore the perspectives of Baltic investors on the Nordic markets, delving into the opportunities, challenges, and strategies for success in this evolving landscape.

- Cross-Border Investment Strategies: How do Baltoscandian investors navigate cross-border investment challenges when entering the Nordic markets?
- Successful case studies and best practices that illustrate effective crossborder investment strategies in the region
- What are the cultural and business differences between Baltoscandia and the Nordic countries, and how do investors overcome them?

Participants

Kaari Kink - Investment Manager, Superangel

Linda Võeras - Early Stage Investor, Karma Ventures

Tim Vaino - Investment Manager, Change Ventures

Is the VC Funding Model Effective for Digital Health, Digital Therapeutics & Medtech?

14:40 - 15:30 MEDTECH & HEALTHTECH LEADERS

- VC funding model how well is this working in reality?
- Surviving the drought creative financing measures in a capital constrained environment
- Has 2024 been the year of consolidation? Who are the winners? Big pharma, big medtech or large healthtech companies?
- Evaluating recent investor decisions Why did you choose to invest? Do investors feel the valuations have been the right size?

Participants

Henrik Cullen - VP of Product, Corti

Ekaterina Gianelli - Venture Partner, Calm/Storm

Lukas Didon - Commercial & Partnerships VP, KRY

Claudia Colciago - Senior Investment Manager, EIFO

Virpi Muhonen - CEO & Co-Founder, Askel Healthcare

Simon Turner - Partner, Sofinnova Partners

Afternoon Break

15:30 - 16:00 Break

VCs & Startups: Allies or Opponents in the Startup Journey?

16:00 - 16:45 BIOTECH LEADERS

In the rapidly evolving landscape of biotech, synergy between (VCs) and biotech startup is pivotal for driving innovation and breakthroughs. This panel discussion aims to dissect the raw realities of the investor-startup relationship, focusing specifically on the interaction between 'young' investors (i.e., non-partners) and 'young' companies (i.e., first-time CEOs).

This panel discussion aims to unravel the untapped potential for more effective collaboration when it comes to investment opportunities, and to have a discussion that is critical, yet constructive, delving into common pitfalls, synergies and addresses how to foster a constructive partnership.

- Beyond common financial incentives, what really drives the investor-startup relationship?
- Mistakes and misunderstandings: Navigating uncharted waters
- When things hit the fan What are the tried and tested approaches to reconcile when setbacks happen?

Participants

Bobby Soni - CBO, BII

João Ribas - Principal, Novo Holdings

Kristian Tryggvason - Co-founder, CEO, Alder Therapeutics

Stephanie Munk - Senior Associate, Sunstone Life Science Ventures

Earning Your Stars & Stripes - The US Playbook

16:00 - 16:45 MEDTECH & HEALTHTECH LEADERS

The biggest market with the clearest opportunity for scale, investors will shy away from medtech and healthtech companies without a clear plan of attack for the US market. This panel looks at what it takes to scale across the pond, and the tips and tricks needed in your back-pocket for success.

- Building your base in the U.S
- Access and regulatory cheatsheet
- Commercialising from a home to international market – mishaps and missteps

Participants

Philip Siberg - CEO, Senzime

Martin Strandberg Larson - Executive Director, Market Access & Medical Affairs, IVD, Veracyte Inc.

Filip Peters - CEO, Acorai

SESSIONS

DAY 1 - TUESDAY 8TH OCTOBER - 08/10/2024

Connecting Nordic & Baltic Innovators With Capital 8th-9th October 2024 Bella Center, Copenhagen, Denmark

Nordic Nexus: Perspectives from Pharma Deal-Making Execs on Collaborating with Biotech Innovators

16:45 - 17:30 BIOTECH LEADERS

This panel convenes top pharmaceutical deal-making executives to delve into the intriguing landscape of Nordic biotech. As the biopharmaceutical sector continues to evolve, the Nordic region has emerged as a hotbed of innovation, boasting a dynamic ecosystem of biotech startups. This session provides a unique platform for deal-making executives to share their perspectives on the Nordic biotech market, exploring the appetite for forging strategic collaborations and deals with these innovative biotech players.

- How are deal-making executives perceiving Nordic innovation in comparison to the rest of the world and what makes a Nordic company more attractive to work with
- Assessing the risk-reward dynamics, weighing the potential benefits of entering the Nordic biotech market against the inherent challenges and uncertainties
- Discussing the degrees of deal structures and negotiation dynamics in collaborations between pharma and biotech, exploring flexible models that accommodate the unique needs and goals of both parties

Participants

Keld Flintholm Jørgensen - SVP & CBO, Lundbeck

Jane Buus Laursen - CVP, Corporate Development, Novo Nordisk

Bradley Hardiman - Senior Director, Ventures, Business development, Astellas Pharma

Elevating Practitioner and Patient Experience - What Truly Matters?

16:45 - 17:30 MEDTECH & HEALTHTECH LEADERS

- Building effective relationships with public healthcare providers
- How can companies improve adoption and implementation?
- What truly augments practitioner and patient experience?
- Has Al adoption brought enough value to healthcare?
- The increasing importance of sustainability for hospitals

Participants

Helle Pappot - Clinical Professor, University of Copenhagen

Eric La Fleche - Managing Director, Siemens Healthineers

Lisbeth Snede - Founder, Patients Unite

Drinks Reception

17:30 - 18:30 Break

SCHEDULE DAY 1 – TUESDAY 8TH OCTOBER - 08/10/2024

TIME	KEYNOTE PLENARY	BREAK	BIOTECH LEADERS	MEDTECH & HEALTHTECH LEADERS
08:00	08:50 - LSX Opening Address			
	08:55 - Live Opening of The Nasdaq Nordic Markets & Nasdaq Welcome			
09:00	09:10 - The Thriving Life Science Ecosystem in the Nordic Region: Evolution, Current Land- scape, and Future Outlook			
	09:50 - The 2030 Vision: The Economic Potential and Future of Nordic Healthcare			
10:00		10:30 - Morning Break		
11:00			11:00 - Nordic Biotechs Beyond Borders: Public- Stage Nordic Biotech's in Today's Markets	11:00 - Our Al Future is Now - Utilising Gen Al & LLMs to Solve Healthcare Challenges
			11:50 - Northern Horizons: Navigating the Nordic Biotech Investment Frontier in 2024 and Beyond	11:40 - Digital Health Reimbursement & Adoption Across Europe - Strategies for Overcoming Fragmented Digital Markets
12:00		12:40 - Lunch Break		
13:00			13:50 - AI – A Game Changer for the Future of Nordic Life Sciences	13:50 - Sourcing Innovation – Deal Activity & Partnerships With Big Strategics
14:00			14:40 - Baltoscandia: The Baltic Investors' Perspective on the Nordic Markets	14:40 - Is the VC Funding Model Effective for Digital Health, Digital Therapeutics & Medtech?
15:00		15:30 - Afternoon Break		

SCHEDULE DAY 1 – TUESDAY 8TH OCTOBER - 08/10/2024

TIME	KEYNOTE PLENARY	BREAK	BIOTECH LEADERS	MEDTECH & HEALTHTECH LEADERS
16:00			16:00 - VCs & Startups: Allies or Opponents in the Startup Journey? 16:45 - Nordic Nexus: Perspectives from Phar-	16:00 - Earning Your Stars & Stripes – The US Playbook 16:45 - Elevating Practitioner and Patient Expe-
			ma Deal-Making Execs on Collaborating with Biotech Innovators	rience - What Truly Matters?
17:00		17:30 - Drinks Reception		

SESSIONS

DAY 2 - WEDNESDAY 9TH OCTOBER - 09/10/2024

Connecting Nordic & Baltic Innovators With Capital 8th-9th October 2024 Bella Center, Copenhagen, Denmark

LSX WELCOME

09:00 - 09:10 BIOTECH LEADERS

Participants

Adam Griffiths - Portfolio Manager, LSX Leaders

LSX Welcome

09:00 - 09:10 MEDTECH & HEALTHTECH LEADERS

Keen to Go Green: Sustainability in Nordic Life Sciences

09:10 - 09:50 BIOTECH LEADERS

The Nordic countries, renowned for their commitment to environmental responsibility, are now extending this ethos to the life science industry. From pharmaceuticals to biotech, the panel will dissect how innovation, ethical practices, and eco-friendly approaches converge to create a sustainable future. Join us as experts unravel the strategies, challenges, and success stories that define the Nordic region's pioneering role in fostering sustainable practices within the dynamic landscape of life science.

- Exploring how the pharmaceutical industry in the Nordic region is embracing circular economy principles. What measures are being taken to reduce waste, recycle materials, and create a more sustainable life cycle for pharmaceutical products?
- The importance of biotech sustainability and investor sentiment
- How are partnerships driving innovation, sharing best practices, and creating a collective commitment to sustainable practices?

Participants

Mette Wendel - Senior Project Manager, Kalundborg Symbiosis

Daniel Eriksson - Founder & CEO, Nordic Center for Sustainable Healthcare

Dorethe Nielsen - VP, Circular for Zero Corporate Environmental Strategy, Novo Nordisk

Driving Investment in Digital Health and Medical Devices in the Nordic Region

09:10 - 09:50

MEDTECH & HEALTHTECH LEADERS

- The Nordic region is one of the most dynamic and innovative in the world – do they investment trends correlate with this?
- Understanding the barriers and opportunities to increase investments in Nordic innovation
- Improving the exit landscape in Nordic healthtech and medtech
- How is the convergence of VC and PE in healthtech & medtech is reshaping the investment and startup landscape?

Participants

Mads Lacoppidan - Partner, EIFO

Shwetank Verma - Co-founder & Managing Partner, Leo Capital

Jonas Jendi - Venture Capital - COO & Investment Director, Industrifonden

Gender Equality in Health? Nordic Perspectives on Women's Health

09:50 - 10:30

In this enlightening panel discussion, we shine a spotlight on the crucial intersection of gender equality and women's health, specifically exploring Nordic perspectives. Our panel of experts will unravel the complexities surrounding gender-based healthcare disparities, shedding light on the innovative approaches, challenges, and success stories that emerge from the Nordic region. Join us as we navigate the landscape of healthcare through a gender lens, seeking to bridge gaps, foster inclusivity, and inspire global conversations on equitable healthcare practices.

- Uncovering groundbreaking research and innovations in women's health from the Nordic region
- How are Nordic countries driving advancements in technologies, treatments, and methodologies that cater specifically to the unique healthcare needs of women?
- Delving into the challenges faced by Nordic nations in achieving gender equality in health and exploring potential strategies for overcoming these hurdles
- What lessons can other regions learn from the Nordic approach, and what lies ahead in the ongoing pursuit of gender-inclusive healthcare systems?

Participants

Anette Steenberg - CEO, Medicon Valley Alliance

Darine Ghanem - General Manager, Roche Denmark

Ina Laura Perkins - CEO, Scandinavian Real Hearts

Innovate, Scale, Profit - Crafting Your Device or Digital Health Commercial Strategy and Business Model

09:50 - 10:30

MEDTECH & HEALTHTECH LEADERS

- · When to start thinking about commercialisation
- The stakeholders you need, and when to engage them
- It's not biotech! The realities of growing your digital health and device company

Participants

Mads-Jacob Vad Kristensen - Venture Developer, People Ventures

Katarina Hedbeck - CEO, Tada Group

Lars Lund - CEO, Hedia

Morning Break

10:30 - 11:00 Break

SESSIONS

DAY 2 - WEDNESDAY 9TH OCTOBER - 09/10/2024

Connecting Nordic & Baltic Innovators With Capital 8th-9th October 2024 Bella Center, Copenhagen, Denmark

Nordic Biotech Brilliance: Unleashing the Talent Magnet for Sustained and Retained Innovation

11:00 - 11:50 BIOTECH LEADERS

In this riveting panel discussion, we unravel the intricate tapestry of attracting and retaining top-tier talent in the Nordic biotech and pharma sector. As the region continues to emerge as a hub for innovation, it is paramount to explore the multifaceted strategies that not only draw skilled professionals but also foster an environment where they thrive and stay. Our expert panelists will share insights, success stories, and challenges, offering a comprehensive guide to companies seeking to build and sustain a powerhouse workforce in the dynamic Nordic biotech and pharma ecosystem.

- Exploring the importance of fostering collaboration between industry, academia, and research institutions to create a robust ecosystem that attracts talent. How can partnerships drive innovation and create a talent magnet for the Nordic region?
- Discussing strategies employed by companies to invest in talent development, training, and upskilling programs
- How can Nordic companies create environments that prioritize the holistic needs of their workforce, ultimately fostering loyalty and satisfaction?
- Examining the impact of diversity and inclusion initiatives on attracting a diverse pool of talent

Participants

Reagan Jarvis - CEO & Co-founder, Anocca, Sweden

Georgina Askeland - Senior Investment Associate, Hadean Ventures

Ulrika Warpman Berglund - CEO, Oxcia

Agnete Fredriksen - Co-founder & CBO, Nykode Therapeutics

Leveraging Nordic Strengths - Remote Patient Monitoring & Redefining the Standard-of-Care

11:00 - 11:40

MEDTECH & HEALTHTECH LEADERS

- Striving towards digitising healthcare services for citizens in the Nordic region
- Looking across the region, how can we increase slow adoption of RPMs in some countries?
- What is required to ensure successful remote monitoring implementations at scale?
- · Using AI to optimise remote patient monitoring

Participants

Alexander Stanke - COO, Preventicus

Philippe Joergensen - CEO, Cortrium

Jhonatan Bringas - CEO, Lapsi Health

May-Britt Moeslund-Hansen - International Healthcare Executive, Former VP Home Therapies, Independent (Former Freesenius)

Achieving Patient Centricity, Scale & Profitability With Digital Therapeutics

11:40 - 12:20

MEDTECH & HEALTHTECH LEADERS

- Which digital therapeutics business models are working in the real world? What is the business model of the future?
- Given the issues with reimbursement, what are companies doing to survive?
- Evaluating the effectiveness of DTx partnerships with Pharma
- · Addressing investor hesitancy and raising funds

Participants

Florian Koerber - Head of Start-Ups & M&A, Flying Health

John Drakenberg - Founder & CEO, Alex Therapeutics

Thomas Thestrup - Principal, Angelini Ventures

Mikaela Odlander - Director and Head of Digital Health EMEA, Orexo

Go West, but is it Best? Unravelling the Nordic and US IPO Markets

11:50 - 12:40 BIOTECH LEADERS

With clear signs of the US IPO market already beginning to rebound at the start of 2024, the Nordic markets are predicted to see promising activity in Q4. We delve into the complexities of the biotech IPO markets, drawing a comparative analysis between the Nordic region and the US market. As biotech companies grapple with the decision of where to launch their initial public offerings, our expert panellists will explore the nuances, opportunities, and challenges presented by both markets. From regulatory landscapes to investor appetites, this session aims to provide valuable insights to guide biotech firms in making strategic decisions that align with their goals and growth trajectories.

- Unpacking the investor landscape in both regions, including the preferences, risk appetites, and trends shaping investment decisions in the biotech sector
- What attracts investors in the Nordic market versus the US, and how can biotechs tailor their strategies accordingly?
- How does the Nordic market's proximity to established European pharmaceutical hubs compare to the US market's global reach? What implications does this have for market penetration and collaboration opportunities?
- Success stories, challenges faced, and lessons learned. What patterns emerge, and how can aspiring biotechs leverage this knowledge to optimize their IPO journey?

Participants

Ulrica Slåne Bjerke - Founder & CIO, Arctic Aurora LifeScience

Lene Gerlach - Partner, Eir Ventures

Vanessa Carle - Partner, Forbion

Lunch Break

12:40 - 14:00 Break

SESSIONS

DAY 2 - WEDNESDAY 9TH OCTOBER - 09/10/2024

Connecting Nordic & Baltic Innovators With Capital 8th-9th October 2024 Bella Center, Copenhagen, Denmark

Arming Against Antimicrobial Resistance: Nordic Strategies in the AMR Battlefield

14:00 - 14:50 BIOTECH LEADERS

We delve into the Nordic region's pivotal role in the global fight against Antimicrobial Resistance (AMR). As one of the most proactive and innovative regions in healthcare, the Nordics are at the forefront of developing solutions to combat the growing threat of drug-resistant infections. Join our esteemed panelists as they explore the landscape of AMR development in the Nordic region, discussing breakthroughs, collaborative efforts, and strategies that can pave the way for a sustainable future against this global health challenge.

- Unveiling the cutting-edge innovations and research breakthroughs emerging from the Nordic region in the quest for new antibiotics
- How are scientists and researchers leveraging technology and collaboration to develop novel solutions to combat drug-resistant infections?
- Discussing collaborative initiatives and partnerships between Nordic countries in the fight against AMR. How are research institutions, pharmaceutical companies, and healthcare systems working together to share knowledge, resources, and expertise to address this global health crisis?
- How are Nordic innovations influencing international policies, and what steps are being taken to ensure a coordinated, global response to the threat of antimicrobial resistance?

Participants

Stine Hasling Mogensen - Chair, Pharmadanmark

Hans Jørn Kolmos - Professor, University of Southern Denmark

Steffen Pierini Lüders - SVP, Corporate Affairs, Novo Nordisk Foundation

Strategies for A Successful Medtech & Healthtech Exit

14:00 - 14:50 MEDTECH & HEALTHTECH LEADERS

The exit is clear, but the path to the door is littered with a myriad of challenges and pitfalls. Medtech and healthtech companies who have deciphered their path through the maze early in their commercial story will prove value to investors and future partners. This panel provides the opportunity for companies to determine their exit roadmap.

- Nordic exit pathways what's out there?
- Strategies for international IPOs and mergers
- Finding your champions

Participants

Magnus Emmoth - CEO, Thoragen

Bjarne Flou - Former CEO, OBI Medical

Mikkel Geertsen - CEO & Co-Founder, Hejdoktor

ATMPs and a New Paradigm Shift for Patients: Initiatives and Ambitions in the Nordics

14:50 - 15:40 BIOTECH LEADERS

New advanced therapies (ATMPs) offer life-changing potential for many patients who battle with serious rare diseases and cancers, the majority of which have very little or no treatment options available. ATMPs therefore have the potential to radically change the landscape of treatment options for these patients, catapulting us into the next generation of medicine and diseases management.

- What success do we currently already have in the Nordics with regards to ATMPs?
- What challenges to ATMPs have and where can we source solutions? Learning from abroad?
- How can we ensure Nordic patients have access to ATMPs? Essential partnerships and financing innovation

Participants

Agnete Kirkeby - Associate Professor, University of Copenhagen and Lund University

Anna Falk - Director, LU-ATMP

David Morrow - Senior Scientific Program Manager and Platform Coordinator, EATRIS

Data, Devices and Digital – The 2030 Personalised Treatment Pathway

14:50 - 15:40

MEDTECH & HEALTHTECH LEADERS

The Nordic Health 2030 Movement aims to improve health at both individual and societal levels by shifting focus from sick care to preventive measures. This panel explores how the region is currently tracking in achieving this goal, and how far it is yet to go.

- · Roadblocks to inter-regional connectivity
- Innovations that are leading the way and what's missing?
- What regional support is available for companies tackling this issue?

Participants

Cecilia Edebo - CEO, Sahlgrenska Science Park

Mattias Kyhlstedt - CEO, Synergus

Saara Malkamäki - Specialist, Health Data 2030, Sitra

Close of Congress

15:40 - 15:45

Break

SCHEDULE DAY 2 - WEDNESDAY 9TH OCTOBER - 09/10/2024

TIME	BIOTECH LEADERS	MEDTECH & HEALTHTECH LEADERS	BREAK
09:00	09:00 - LSX WELCOME 09:10 - Keen to Go Green: Sustainability in Nordic Life Sciences 09:50 - Gender Equality in Health? Nordic Perspectives on Women's Health	09:00 - LSX Welcome 09:10 - Driving Investment in Digital Health and Medical Devices in the Nordic Region 09:50 - Innovate, Scale, Profit - Crafting Your Device or Digital Health Commercial Strategy and Business Model	
10:00			10:30 - Morning Break
11:00	11:00 - Nordic Biotech Brilliance: Unleashing the Talent Magnet for Sustained and Retained Innovation 11:50 - Go West, but is it Best? Unravelling the Nordic and US IPO Markets	11:00 - Leveraging Nordic Strengths - Remote Patient Monitoring & Redefining the Standard-of-Care 11:40 - Achieving Patient Centricity, Scale & Profitability With Digital Therapeutics	
12:00			12:40 - Lunch Break
14:00	14:00 - Arming Against Antimicrobial Resistance: Nordic Strategies in the AMR Battlefield 14:50 - ATMPs and a New Paradigm Shift for Patients: Initiatives and Ambitions in the Nordics	14:00 - Strategies for A Successful Medtech & Healthtech Exit 14:50 - Data, Devices and Digital – The 2030 Personalised Treatment Pathway	
15:00			15:40 - Close of Congress